ES502 / Shanghai Essight Biotechnology - LARVOL DELTA

Shanghai Essight Biotechnology Co., Ltd. announced that ES502 Injection has received FDA approval to proceed with a Phase I clinical trial for patients with advanced solid tumors harboring RAS G12V mutations (KRAS/NRAS/HRAS) (flcube.com) - "ES502 becomes the world’s first TCR×CD3 bispecific T‑cell engager (TCE) targeting the RAS G12V neoantigen to enter clinical development, with potential to address 30–70% of global patients carrying this prevalent oncogenic driver mutation."

IND • New P1 trial • Solid Tumor